Unlike Aduhelm at least Relyvrio doesn't cause hea
Post# of 145810
A.L.S. for which it's approved is also on our disease list. Leronlimab also reduces ROS and downregulates cytochrome c, caspase 1, 3 and 9 (possibly others) and has other mechanisms to lower inflammation, cell damage and mitochondrial damage. Given the broader range of action I think leronlimab would be far superior.
It would be nice to at least have mouse studies in A.L.S. and some other diseases just as proof of concept.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)